#news
-
NOVITÀ
-
NOVITÀ
Thalassemia Foundation of Canada to Host its National Thalassemia Conference on October 23-24
The Thalassemia Foundation of Canada, a long-time member of TIF, will be holding its 2-day Virtual National Conference on Thalassaemia this weekend, October 23-24, at 12:00-16:00 EDT. The Conference aims at…
Leggi di più » -
NOVITÀ
TIF Takes Active Part In The 71st Session of the WHO Regional Committee for Europe
TIF has participated in the 71st session of the WHO Regional Committee for Europe between 13–15 September 2021, which gathered six hundred high-level delegates, including over 30 Health Ministers from…
Leggi di più » -
NOVITÀ
TIF Participates in EMA’s Annual Training Day 2020
TIF has participated in the Annual Training Day of the European Medicines Agency (EMA), held on 23 October 2020. TIF participants, Ms Lily Cannon (TIF Operations Manager) and Ms Eleni…
Leggi di più » -
TIF News (IT)
TIF Webinar Fridays Are Back With A New Session on “Heart Disease In Thalassaemia”
This Friday, 23 October 2020, at 15:00 EEST/13:00 BST, get ready to join Prof. Malcolm Walker and Dr. Dimitris Farmakis in our webinar on ”Heart Disease In Thalassaemia” for Patients/Parents,…
Leggi di più » -
NOVITÀ
Johnson & Johnson Pauses Clinical Trials For Its Covid-19 Vaccine Over Participant’s Illness
Johnson & Johnson has paused its Covid-19 vaccine trial due to an “unexplained illness” in a participant, the company confirmed yesterday evening. The pharmaceutical giant was unclear if the patient…
Leggi di più » -
NOVITÀ
Hidden Victims Of The Pandemic: Blood Bank Stocks Run Low As India’s Healthcare System Buckles
As public healthcare resources are redirected to halt the spread of coronavirus, victims of other life-threatening diseases pay the ultimate price. This recent news story, published by The Telegraph, depicts…
Leggi di più » -
NOVITÀ
-
Clinical News
Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease
Fulcrum Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that FTX-6058, its investigational treatment for sickle cell disease (SCD) and…
Leggi di più » -
NOVITÀ
Pancyprian Thalassaemia Conference 2020
Τhe Pancyprian Thalassaemia Conference 2020 was successfully held on Saturday, 26 September, to discuss the modern scientific and other developments concerning thalassemia in Cyprus and worldwide. As a result of…
Leggi di più »